title: The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.
abstract: OBJECTIVE
  To prospectively evaluate the diagnostic value of combined PET/CT in detecting a malignant tumor in patients with no previous cancer history, presenting with a pelvic mass.
  
  
  METHODS
  From September 2004 to March 2006, 101 patients (median age=60 years, range=24-85 years) with a Risk of Malignancy Index (RMI)>150 based on serum CA-125, ultrasound examinations (US) and menopausal state, were referred to PET/CT within 2 weeks prior to standard surgery/debulking of a pelvic tumor. Histological specimens from 97 patients were evaluated and the histological diagnoses were compared to the PET/CT results to calculate the diagnostic value of PET/CT in differentiating between malignant and borderline/benign tumors. Four patients refrained from surgery or biopsy.
  
  
  RESULTS
  The average serum CA-125 in the 97 studied patients was 784 U/ml (range=22-9665 U/ml). PET/CT demonstrated areas of abnormally increased metabolic activity considered highly suspicious for malignant tumor in 60 patients (62%). In 37 patients (38%) the tumors were considered benign on PET/CT. Histopathology showed benign tumors in 40 patients and malignant tumors in 57 patients. The sensitivity and specificity for PET/CT in diagnosing a malignant pelvic tumor were 100% (57/57) and 92.5% (37/40), respectively (P<0.00005).
  
  
  CONCLUSIONS
  Combined PET/CT demonstrates high diagnostic value in identifying primary ovarian cancer in patients with a pelvic mass of unknown origin and RMI>150. We suggest PET/CT as the image modality of choice when US shows a pelvic tumor and additional information prior to surgery is needed.
authors.affiliation: Dept. of Oncology, 5073, The Finsen Center, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. signerisum@hotmail.com
authors.forename: Signe
authors.initials: S
authors.lastname: Risum
authors.forename: Claus
authors.initials: C
authors.lastname: Høgdall
authors.forename: Annika
authors.initials: A
authors.lastname: Loft
authors.forename: Anne K
authors.initials: AK
authors.lastname: Berthelsen
authors.forename: Estrid
authors.initials: E
authors.lastname: Høgdall
authors.forename: Lotte
authors.initials: L
authors.lastname: Nedergaard
authors.forename: Lene
authors.initials: L
authors.lastname: Lundvall
authors.forename: Svend A
authors.initials: SA
authors.lastname: Engelholm
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D018394:CA-125 Antigen; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18